136 related articles for article (PubMed ID: 17652061)
1. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
Santisteban M; Nieto Y; De la Cruz S; Aristu J; Zubieta JL; Fernández Hidalgo O
Clin Transl Oncol; 2007 Jul; 9(7):465-7. PubMed ID: 17652061
[TBL] [Abstract][Full Text] [Related]
2. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Wong ET; Tishler R; Barron L; Wu JK
Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
[TBL] [Abstract][Full Text] [Related]
3. Rituximab maintenance therapy in central nervous system lymphoma?
Murawski N; Pfreundschuh M
Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
[No Abstract] [Full Text] [Related]
4. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Pitini V; Arrigo C; Righi M
Cancer; 2004 Dec; 101(12):2900-1; author reply 2901-2. PubMed ID: 15529311
[No Abstract] [Full Text] [Related]
5. Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
Murakami M; Fujimaki T; Asano S; Nakaguchi H; Yamada SM; Hoya K; Yamazaki K; Ishida Y; Matsuno A
Yonsei Med J; 2011 Nov; 52(6):1031-4. PubMed ID: 22028172
[TBL] [Abstract][Full Text] [Related]
6. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
[TBL] [Abstract][Full Text] [Related]
7. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
Yamanaka R
Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
[TBL] [Abstract][Full Text] [Related]
8. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
Glass J; Won M; Schultz CJ; Brat D; Bartlett NL; Suh JH; Werner-Wasik M; Fisher BJ; Liepman MK; Augspurger M; Bokstein F; Bovi JA; Solhjem MC; Mehta MP
J Clin Oncol; 2016 May; 34(14):1620-5. PubMed ID: 27022122
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
[TBL] [Abstract][Full Text] [Related]
10. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Enting RH; Demopoulos A; DeAngelis LM; Abrey LE
Neurology; 2004 Sep; 63(5):901-3. PubMed ID: 15365145
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
Nayak L; Abrey LE; Drappatz J; Gilbert MR; Reardon DA; Wen PY; Prados M; Deangelis LM; Omuro A;
Leuk Lymphoma; 2013 Jan; 54(1):58-61. PubMed ID: 22656234
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Wong ET
Neurology; 2005 Mar; 64(5):934; author reply 934. PubMed ID: 15753455
[No Abstract] [Full Text] [Related]
14. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
[TBL] [Abstract][Full Text] [Related]
15. First-line therapy with temozolomide induces regression of primary CNS lymphoma.
Herrlinger U; Küker W; Platten M; Dichgans J; Weller M
Neurology; 2002 May; 58(10):1573-4. PubMed ID: 12034807
[No Abstract] [Full Text] [Related]
16. Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.
Wang XX; Huang HQ; Bai B; Cai QQ; Cai QC; Gao Y; Xia YF; Xia ZJ; Jiang WQ
Leuk Lymphoma; 2014 Nov; 55(11):2497-501. PubMed ID: 24605911
[TBL] [Abstract][Full Text] [Related]
17. Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response.
Lerro KA; Lacy J
J Neurooncol; 2002 Sep; 59(2):165-8. PubMed ID: 12241110
[TBL] [Abstract][Full Text] [Related]
18. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.
Omuro AM; Taillandier L; Chinot O; Carnin C; Barrie M; Hoang-Xuan K
J Neurooncol; 2007 Nov; 85(2):207-11. PubMed ID: 17896079
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]